<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02290951</url>
  </required_header>
  <id_info>
    <org_study_id>R1979-HM-1333</org_study_id>
    <secondary_id>2015-004491-30</secondary_id>
    <nct_id>NCT02290951</nct_id>
  </id_info>
  <brief_title>Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies</brief_title>
  <acronym>ELM-1</acronym>
  <official_title>An Open-Label, Multi-Center Phase 1 Study to Investigate the Safety and Tolerability of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients With CD20+ B-Cell Malignancies Previously Treated With CD20-Directed Antibody Therapy (ELM-1)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study has two parts with distinct study objectives and study design. In part A,&#xD;
      odronextamab is studied as an intravenous (IV) administration with a dose escalation and a&#xD;
      dose expansion phase for B-NHL and CLL. The dose escalation phase for B-NHL and the CLL study&#xD;
      are closed at the time of protocol amendment 17. In part B, odronextamab is studied as a&#xD;
      subcutaneous (SC) administration with a dose finding and a dose expansion phase for B-NHL.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 9, 2015</start_date>
  <completion_date type="Anticipated">April 17, 2025</completion_date>
  <primary_completion_date type="Anticipated">April 17, 2025</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety/overall frequency of adverse events</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Part A and B</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety/dose limiting toxicities (DLTs)</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>Part A and B</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Antitumor activity as measured by the objective response rate (ORR)</measure>
    <time_frame>Through study completion, an average of 24 months</time_frame>
    <description>Expansion Cohorts:&#xD;
• Diffuse large B-cell lymphoma (DLBCL) after failure of CAR-T therapy&#xD;
Part A</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Concentration of odronextamab)</measure>
    <time_frame>Up to 10 months</time_frame>
    <description>Peak plasma concentration (Cmax) of odronextamab&#xD;
Part A and B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity (Anti-odronextamab antibodies)</measure>
    <time_frame>Up to 15 months</time_frame>
    <description>Anti-odronextamab antibodies and neutralizing antibodies (NAb)&#xD;
Part A and B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>Through study completion, an average of 24 months</time_frame>
    <description>For dose escalation portion and expansion cohorts:&#xD;
Aggressive lymphoma expansion cohort 2&#xD;
FL grade 1-3a expansion cohorts 1 and 2 (Part A)&#xD;
For dose escalation and dose expansion cohorts:&#xD;
FL grade 1-3a&#xD;
DLBCL&#xD;
DLBCL post CAR T failure (Part B)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Up to 48 months</time_frame>
    <description>Part A and B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Until death or lost to follow-up/ withdrawal, approximately up to 48 months</time_frame>
    <description>Part A and B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>Until progression, approximately up to 48 months</time_frame>
    <description>Part A and B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimal residual disease (MRD) for patients with CLL</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Part A</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Complete Response (DOCR)</measure>
    <time_frame>Until progression, approximately up to 48 months</time_frame>
    <description>Part B</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">298</enrollment>
  <condition>Non-Hodgkin Lymphoma</condition>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>1N Part A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DLBCL post CAR-T</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1N Part B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2N Part B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DLBCL</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Odronextamab multiple dose levels</intervention_name>
    <description>Administered by intravenous (IV) infusion or subcutaneous (SC) injection</description>
    <arm_group_label>1N Part A</arm_group_label>
    <arm_group_label>1N Part B</arm_group_label>
    <arm_group_label>2N Part B</arm_group_label>
    <other_name>REGN1979</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Have documented CD20+ B-cell malignancy, with active disease not responsive to prior&#xD;
             therapy, for whom no standard of care options exists, and for whom treatment with an&#xD;
             anti-CD20 antibody may be appropriate:&#xD;
&#xD;
               -  Part A (IV administration) B-NHL confirmed by National Cancer Institute (NCI)&#xD;
                  working group criteria&#xD;
&#xD;
               -  Part B (SC administration): Confirmed diagnosis of B-NHL requiring therapy as&#xD;
                  defined by WHO classification 2017&#xD;
&#xD;
          2. Patients with B-NHL must have had prior treatment with an anti-CD20 antibody therapy.&#xD;
&#xD;
               -  For the inclusion in the disease-specific expansion cohort enrolling DLBCL&#xD;
                  patients after failure of CAR-T therapy, the patient must have recovered from the&#xD;
                  toxicities of the lymphodepletion therapy and CAR-T infusion.&#xD;
&#xD;
               -  For inclusion in Part B, patients must have FL grade 1-3a or DLBCL (with or&#xD;
                  without prior CAR-T) per the criteria above, and:&#xD;
&#xD;
               -  Patients with FL grade 1-3a and DLBCL must have received at least 2 prior lines&#xD;
                  of systemic therapy, including an anti-CD20 antibody and an alkylating agent&#xD;
&#xD;
          3. All patients must have at least one bi-dimensionally measurable lesion ≥1.5 cm)&#xD;
             documented by CT or MRI scan, if CT scan is not feasible.&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group (ECOG) performance status ≤1&#xD;
&#xD;
          5. Life expectancy of at least 6 months&#xD;
&#xD;
          6. Adequate bone marrow function as described in the protocol&#xD;
&#xD;
          7. Adequate organ function as described in the protocol&#xD;
&#xD;
          8. Willingness to undergo mandatory tumor biopsy pretreatment, if in the opinion of the&#xD;
             investigator, the patient has an accessible lesion that can be biopsied without&#xD;
             significant risk to the patient.&#xD;
&#xD;
          9. Willing and able to comply with clinic visits and study-related procedures&#xD;
&#xD;
         10. Provide signed informed consent or legally acceptable representative&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Primary central nervous system (CNS) lymphoma or known or suspected CNS involvement by&#xD;
             non-primary CNS NHL&#xD;
&#xD;
          2. History of or current relevant CNS pathology such as&#xD;
&#xD;
               -  Epilepsy, seizure, paresis, aphasia, apoplexia, severe brain injuries, cerebellar&#xD;
                  disease, organic brain syndrome, psychosis, or&#xD;
&#xD;
               -  Evidence for presence of inflammatory lesions and/or vasculitis on cerebral MRI&#xD;
&#xD;
          3. Standard anti-lymphoma chemotherapy (non-biologic) or radiotherapy within 28 days&#xD;
             prior to first administration of study drug&#xD;
&#xD;
          4. Infection with human immunodeficiency virus (HIV) or chronic infection with hepatitis&#xD;
             B virus (HBV) or hepatitis C virus (HCV). Patients with hepatitis B (HepBsAg+) who&#xD;
             have controlled infection (serum hepatitis B virus DNA that is below the limit of&#xD;
             detection AND receiving anti-viral therapy for hepatitis B) are permitted upon&#xD;
             consultation with the physician managing the infection.&#xD;
&#xD;
          5. Patients who have received a live vaccination within 28 days of first dose of study&#xD;
             treatment&#xD;
&#xD;
        Note: Other protocol Inclusion/Exclusion criteria apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Management</last_name>
    <role>Study Director</role>
    <affiliation>Regeneron Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials Administrator</last_name>
    <email>clinicaltrials@regeneron.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California, Irvine</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute (Massachusetts General Hospital and Beth Israel)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rutgers Cancer Institute of New Jersey</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Wurzburg</name>
      <address>
        <city>Wurzburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 7, 2014</study_first_submitted>
  <study_first_submitted_qc>November 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 14, 2014</study_first_posted>
  <last_update_submitted>October 18, 2021</last_update_submitted>
  <last_update_submitted_qc>October 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diffuse large B-cell lymphoma (DLBCL)</keyword>
  <keyword>Follicular lymphoma (FL)</keyword>
  <keyword>Aggressive lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

